Q2 2016 13F Holders as of 30 Jun 2016
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
166M
-
Number of holders
-
59
-
Total 13F shares, excl. options
-
18.8M
-
Shares change
-
+1.8M
-
Total reported value, excl. options
-
$149M
-
Value change
-
+$16M
-
Number of buys
-
43
-
Number of sells
-
-10
-
Price
-
$10.21
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q2 2016
65 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q2 2016.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 59 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.8M shares
of 166M outstanding shares and own 11.38% of the company stock.
Largest 10 shareholders include FMR LLC (5.41M shares), Canaan Partners IX LLC (4.24M shares), DEERFIELD MANAGEMENT CO (943K shares), Tekla Capital Management LLC (756K shares), PERCEPTIVE ADVISORS LLC (742K shares), Redmile Group, LLC (734K shares), BVF INC/IL (606K shares), VHCP Management II, LLC (578K shares), BlackRock Advisors LLC (542K shares), and BlackRock Fund Advisors (527K shares).
This table shows the top 59 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.